Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Merck Announces Final Results From The STARTMRK Study

Merck (MRK: Quote), known as MSD outside the United States and Canada, announced final results from the STARTMRK study which is the longest double-blind Phase III non-inferiority study evaluating an integrase inhibitor in treatment-naïve adults with HIV-1.

The company said that in this pre-specified exploratory analysis of ISENTRESS 400 mg Film-coated Tablets in combination therapy in previously untreated adult HIV-1 patients, virologic efficacy was better than the efavirenz-based regimen at 240 weeks. At all pre-specified time points, the regimen containing ISENTRESS had fewer drug-related adverse events versus the comparator.

The 240-week analysis showed that the regimen containing ISENTRESS demonstrated long-term viral suppression and a greater immunologic response, as well as a proven safety and tolerability profile, the company added.

ISENTRESS is an integrase inhibitor indicated in combination with other antiretroviral or ARV agents for the treatment of HIV-1 infection in adults. This indication is based on analyses of plasma HIV-1 RNA levels in three double-blind controlled studies of ISENTRESS.

Severe, potentially life-threatening and fatal skin reactions have been reported with ISENTRESS. Additionally, during the initial phase of treatment, immune reconstitution syndrome may occur, Merck noted.

Commenting about ISENTRESS, the company stated that it is currently the first and only approved integrase inhibitor for the treatment of HIV-1. ISENTRESS works by inhibiting the insertion of HIV-1 DNA into human DNA by the integrase enzyme and has demonstrated rapid antiviral activity.

Other HIV-1 drugs in use inhibit two other enzymes critical to the HIV-1 replication process - protease and reverse transcriptase, but ISENTRESS is the only approved drug that inhibits the integrase enzyme.

Register
To receive FREE breaking news email alerts for Merck & Co Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.